Location: Home > Pharma China Web Edition
  • search
  • go
    • The Market
    China’s Pharmaceutical SOEs Maintain Stable Increase in Profitability in 3Q 11/2/2005
    China’s pharmaceutical State-owned enterprises (SOEs) have maintained a stable increase in profits during the first three quarters of this year, although business cost stayed on an upward track, according to the State-owned Assets Supervision and Administration Commission (SASAC).

    The statistics from SASAC show that during the period, 23 key pharmaceutical SOEs’ net revenues totaled RMB 89.82 billion with an increase of 13.7% from same period of last year but their business costs increased to RMB 71.89 billion by 15.8%, 2.1 percentage points quicker than the increase rate of their net revenues. As a result, they achieved net profit of RMB 3.35 billion, 7.4% more than a year ago.

    SASAC also shows that the value-added output of these twenty-three enterprises amounts to RMB 42.21 billion, an increase of 12.5% over the same period last year.
    Relate News
    more
  • Site map | Contact Us | Links
  • © Wicon International Group